As for clinical, that comes from FATE and NKTX (using healthy donor), even though there are some differences between the programs in the same indications. From memory, in R/R NHL, FATE's best efficacy was achieved at a (much) lower dose (+/- rituximab), while NKTX had to go up to a billion across three doses (no rituximab).

Liked By
Spread the love. Be the first to like this post!
Recent IPSC News
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 02/06/2023 11:53:26 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 02/06/2023 11:53:05 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 02/06/2023 11:52:27 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 02/06/2023 11:51:19 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 02/06/2023 11:50:35 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 02/06/2023 11:50:04 PM
- Century Therapeutics to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/01/2023 12:00:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/09/2023 12:02:16 PM
- Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026 • GlobeNewswire Inc. • 01/05/2023 09:01:00 PM
- Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/04/2023 12:00:00 PM
- Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference • GlobeNewswire Inc. • 11/22/2022 12:00:00 PM
- Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates • GlobeNewswire Inc. • 11/11/2022 12:00:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/10/2022 10:19:05 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/10/2022 12:32:52 PM
- Quarterly Report (10-q) • Edgar (US Regulatory) • 11/10/2022 12:32:06 PM
- Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/10/2022 12:30:00 PM
- Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022 • GlobeNewswire Inc. • 11/02/2022 11:05:00 AM
- Amended Statement of Beneficial Ownership (sc 13d/a) • Edgar (US Regulatory) • 10/11/2022 06:10:29 PM
- Century Therapeutics to Present at the SITC 37th Annual Meeting • GlobeNewswire Inc. • 10/05/2022 08:05:00 PM
- Initial Statement of Beneficial Ownership (3) • Edgar (US Regulatory) • 10/03/2022 08:09:15 PM
- Initial Statement of Beneficial Ownership (3) • Edgar (US Regulatory) • 10/03/2022 08:05:25 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 10/03/2022 11:10:02 AM
- Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors • GlobeNewswire Inc. • 10/03/2022 11:00:00 AM
- Century Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference • GlobeNewswire Inc. • 09/26/2022 11:00:00 AM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 09/08/2022 11:32:14 AM
FEATURED American Green (OTC:ERBB) Signs $12 Million Dollar Non-Binding Letter of Intent for Funding of its Cypress Chill Cannabis Grow Facility PHOENIX, AZ (January 7, • Feb 7, 2023 9:17 AM
FEATURED Goldshore Intersects 9.46 g/t Au over 7.45m in the Southwest Zone • Feb 7, 2023 7:00 AM
Chairman & CEO Joshua Sodaitis Announces Annual Letter to Shareholders • PTOP • Feb 7, 2023 10:00 AM
American Green (OTC:ERBB) Signs $12 Million Dollar Non-Binding Letter of Intent for Funding of its Cypress Chill Cannabis Grow • ERBB • Feb 7, 2023 9:17 AM
Good Gaming Inc. To Launch Its First Extreme Game Mob Wars For Advanced Players As Minecraft and Roblox Continue To Experience Rapid Growth • GMER • Feb 7, 2023 8:30 AM
B2Digital's B2 Fighting Series Kicks Off 2023 with New Single-Event Company Record at B2FS 178 • BTDG • Feb 7, 2023 8:30 AM